US FDA to discuss OTC switch for adapalene

19 February 2016 - Deborah Wilkes

Archived

An advisory committee to the US Food and Drug Administration (FDA) is set to consider Galderma's application to switch adapalene – the active ingredient of its acne medicine Differin – from prescription to OTC status.

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: